Patents by Inventor Eugen F. Mesaros

Eugen F. Mesaros has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF
    Publication number: 20230312481
    Abstract: The present disclosure includes certain substituted (phthalazin-1-ylmethyl)ureas, N-(phthalazin-1-ylmethyl)amides, and analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
    Type: Application
    Filed: June 7, 2021
    Publication date: October 5, 2023
    Inventors: Andrew G. Cole, Bruce D. Dorsey, Benjamin J. Dugan, Yi Fan, Steven G. Kultgen, Eugen F. Mesaros, Michael J. Sofia
  • SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME
    Publication number: 20230295115
    Abstract: The present disclosure includes substituted isoquinolinylmethyl amides, or analogues thereof, and compositions comprising the same, that can be used to treat, ameliorate, and/or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
    Type: Application
    Filed: June 7, 2021
    Publication date: September 21, 2023
    Inventors: Andrew G. Cole, Bruce D. Dorsey, Benjamin J. Dugan, Yi Fan, Steven G. Kultgen, Eugen F. Mesaros, Michael J. Sofia
  • SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME
    Publication number: 20230108906
    Abstract: The present disclosure includes in one aspect substituted arylmethyl ureas, substituted heteroarylmethyl ureas, or analogues thereof, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 6, 2023
    Inventors: Andrew G. Cole, Bruce D. Dorsey, Yi Fan, Steven G. Kultgen, Eugen F. Mesaros
  • SOLID FORMS OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF
    Publication number: 20220194964
    Abstract: Disclosed herein are crystalline forms of ((2-Ethylbutanoyl)oxy)methyl (R)-2-hydroxy-3-propionamido-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylate. Also disclosed herein are methods of treating a bacterial with a crystalline form of ((2-Ethylbutanoyl)oxy)methyl (R)-2-hydroxy-3-propionamido-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylate.
    Type: Application
    Filed: April 1, 2020
    Publication date: June 23, 2022
    Inventors: Christopher J. BURNS, Lawrence ROSEN, Stephen M. CONDON, Eugen F. MESAROS, Allison L. ZULLI, Robert E. Lee TROUT, Yijun DENG, Steven A. BOYD, Robert SIMPSON
  • Penicillin-binding protein inhibitors
    Patent number: 11332485
    Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: May 17, 2022
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Guo-Hua Chu, Jodie Hamrick, Matthew Lucas, Steven A. Boyd, Allison L. Zulli, Eugen F. Mesaros, Stephen M. Condon, Robert E. Lee Trout, Cullen L. Myers
  • Penicillin-binding protein inhibitors
    Patent number: 11267826
    Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: March 8, 2022
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Guo-Hua Chu, Randy W. Jackson, Jodie Hamrick, Matthew Lucas, Steven A. Boyd, Jiangchao Yao, Eugen F. Mesaros
  • PENICILLIN-BINDING PROTEIN INHIBITORS
    Publication number: 20210198288
    Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: May 23, 2019
    Publication date: July 1, 2021
    Inventors: Christopher J. BURNS, Denis DAIGLE, Guo-Hua CHU, Jodie HAMRICK, Steven A. BOYD, Allison L. ZULLI, Eugen F. MESAROS, Stephen M. CONDON, Robert E. Lee TROUT, Cullen L. MYERS, Zhenrong XU
  • PENICILLIN-BINDING PROTEIN INHIBITORS
    Publication number: 20200157123
    Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: May 25, 2018
    Publication date: May 21, 2020
    Inventors: Christopher J. BURNS, Denis DAIGLE, Guo-Hua CHU, Jodie HAMRICK, Matthew LUCAS, Steven A. Boyd, Allison L. ZULLI, Eugen F. MESAROS, Stephen M. CONDON, Robert E. Lee TROUT, Cullen L. MYERS
  • PENICILLIN-BINDING PROTEIN INHIBITORS
    Publication number: 20200102331
    Abstract: Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: May 25, 2018
    Publication date: April 2, 2020
    Inventors: Christopher J. BURNS, Denis DAIGLE, Guo-Hua CHU, Randy W. JACKSON, Jodie HAMRICK, Matthew Lucas, Steven A. BOYD, Jiangchao YAO, Eugen F. MESAROS
  • Beta-lactamase inhibitors
    Patent number: 10464952
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: November 5, 2019
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson, Jodie Hamrick, Allison L. Zulli, Eugen F. Mesaros, Steven A. Boyd
  • Azaquinazoline inhibitors of atypical protein kinase C
    Patent number: 10414763
    Abstract: The present application provides a compound of formula (I) and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: September 17, 2019
    Assignee: Cancer Research Technology Limited
    Inventors: Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel J T Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. A. Roffey, Christelle N. Soudy, Craig A. Zificsak, Allison L. Zulli
  • BETA-LACTAMASE INHIBITORS
    Publication number: 20180291039
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Application
    Filed: June 7, 2018
    Publication date: October 11, 2018
    Inventors: Christopher J. BURNS, Daniel C. PEVEAR, Robert E. Lee TROUT, Randy W. Jackson, Jodie HAMRICK, Allison L. ZULLI, Eugen F. MESAROS, Steven A. BOYD
  • Azaquinazoline inhibitors of Atypical protein Kinase C
    Patent number: 9914730
    Abstract: The present application provides azaquinazoline compounds as defined herein. This application further describes compositions comprising the same. These azaquinazoline compounds and their salts have atypical protein kinase C (“aPKC”) inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: March 13, 2018
    Assignee: Cancer Research Technology Limited
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J Dugan, Katherine M. Fowler, Robert L Hudkins, Eugen F. Mesaros, Nathaniel J. T. Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. Roffey, Christelle N. Soudy, Ming Tao, Craig A. Zificsak, Allison L. Zulli
  • Azaquinazoline inhibitors of atypical protein kinase C
    Patent number: 9896446
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 20, 2018
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Robert L. Hudkins, Eugen F. Mesaros, Gregory R. Ott, Craig A. Zificsak, Allison L. Zulli, Ming Tao, Katherine M. Fowler, Emma L. Morris, Gregoire A. Pave, Jonathan R. A. Roffey, Nathaniel J. T. Monck, Christelle N. Soudy, Ikeoluwa Olowoye
  • PYRROLOTRIAZINES AS ALK INHIBITORS
    Publication number: 20160347756
    Abstract: This application provides compounds of the general formula (I) and/or a salt thereof, where X, R1 and R2 are as defined herein. Compositions and therapeutic uses are also described.
    Type: Application
    Filed: August 9, 2016
    Publication date: December 1, 2016
    Inventors: Ralph C. Haltiwanger, Eugen F. Mesaros, Gregory R. Ott
  • Pyrrolotriazines as ALK inhibitors
    Patent number: 9440984
    Abstract: This application provides compounds of the general formula (I) and/or a salt thereof, where X, R1 and R2 are as defined herein. Compositions and therapeutic uses are also described.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: September 13, 2016
    Assignee: Cephalon, Inc.
    Inventors: Ralph C. Haltiwanger, Eugen F. Mesaros, Gregory R. Ott
  • Azaquinazoline Inhibitors of Atypical Protein Kinase C
    Publication number: 20160102094
    Abstract: The present application provides a compound of formula (1) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 14, 2016
    Applicants: IGNYTA, INC., Cancer Research Technology Limited
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Robert L. Hudkins, Eugen F. Mesaros, Gregory R. Ott, Craig A. Zificsak, Allison L. Zulli, Ming Tao, Katherine M. Fowler, Emma L. Morris, Gregoire A. Pave, Jonathan R.A. Roffey, Nathaneil J.T. Monck, Christelle N. Soudy, Ikeoluwa Olowoye
  • PYRROLOTRIAZINES AS ALK INHIBITORS
    Publication number: 20160068535
    Abstract: This application provides compounds of the general formula (I) and/or a salt thereof, where X, R1 and R2 are as defined herein. Compositions and therapeutic uses are also described.
    Type: Application
    Filed: November 18, 2015
    Publication date: March 10, 2016
    Inventors: Ralph C. Haltiwanger, Eugen F. Mesaros, Gregory R. Ott
  • Azaquinazoline Inhibitors Of Atypical Protein Kinase C
    Publication number: 20150274720
    Abstract: The present application provides a compound of formula (I) and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.
    Type: Application
    Filed: March 25, 2015
    Publication date: October 1, 2015
    Inventors: Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel JT Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R.A. Roffey, Christelle N. Soudy, Craig A. Zificsak, Allison L. Zulli
  • Azaquinazoline Inhibitors of Atypical Protein Kinase C
    Publication number: 20140113882
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 24, 2014
    Applicants: Cancer Research Technology Limited, Cephalon, Inc.
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel J.T. Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. Roffey, Christelle N. Soudy, Ming Tao, Craig A. Zificsak, Allison L. Zulli